Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect-Reference-Cited by-同舟云学术

Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect

Published:2020-09-16 Issue:561 Volume:12 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Bachireddy Pavan¹²³⁴^ORCID,Ennis Christina¹,Nguyen Vinhkhang N.¹,Gohil Satyen H.¹³⁵^ORCID,Clement Kendell³⁶^ORCID,Shukla Sachet A.¹³^ORCID,Forman Juliet¹³,Barkas Nikolaos³^ORCID,Freeman Samuel³^ORCID,Bavli Natalie⁷,Elagina Liudmila³,Leshchiner Ignaty³,Mohammad Arman W.³,Mathewson Nathan D.²³⁸^ORCID,Keskin Derin B.¹²³^ORCID,Rassenti Laura Z.⁹,Kipps Thomas J.⁹^ORCID,Brown Jennifer R.¹²³⁴^ORCID,Getz Gad²³⁶¹⁰^ORCID,Ho Vincent T.¹²⁴,Gnirke Andreas³,Neuberg Donna¹¹^ORCID,Soiffer Robert J.¹²⁴,Ritz Jerome¹²⁴,Alyea Edwin P.¹²⁴,Kharchenko Peter V.¹²¹³^ORCID,Wu Catherine J.¹²³⁴^ORCID

Affiliation:

1. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.

2. Harvard Medical School, Boston, MA 02115, USA.

3. Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.

4. Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA.

5. Department of Academic Haematology, University College London, London WC1E 6BT, UK.

6. Center for Cancer Research, Massachusetts General Hospital, Boston, MA 02114, USA.

7. Division of Hematology and Oncology, UT Southwestern, Dallas, TX 75390, USA.

8. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

9. Moores Cancer Center, University of California, San Diego, La Jolla, CA 92037, USA.

10. Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA.

11. Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

12. Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.

13. Harvard Stem Cell Institute, Cambridge, MA 02138, USA.

Abstract

The clinical kinetics of CLL relapse after stem cell transplant are underwritten by distinct genetic and epigenetic evolutionary trajectories.

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

National Cancer Institute

Leukemia and Lymphoma Society

Damon Runyon Cancer Research Foundation

American Society of Hematology

Be The Match Foundation

Kay Kendall Leukaemia Fund

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference49 articles.

1. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer

2. Haematological malignancies: at the forefront of immunotherapeutic innovation

3. The Evolving Role of Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia

4. How and when I do allogeneic transplant in CLL

5. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic identification of minor histocompatibility antigens predicts outcomes of allogeneic hematopoietic cell transplantation;Nature Biotechnology;2024-08-21

2. Single-cell genomics-based immune and disease monitoring in blood malignancies;Clinical Hematology International;2024-06-14

3. The molecular map of CLL and Richter's syndrome;Seminars in Hematology;2024-04

4. Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance;Experimental Hematology & Oncology;2024-01-30

5. Hematopoietic Cell Transplantation and Other Cellular Therapies for Chronic Lymphocytic Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024